Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

54.7K
Overview
54.7K
Vaccines01:21

Vaccines

63
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
63
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.5K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.5K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Cross-reactivity00:42

Cross-reactivity

34.1K
Overview
34.1K
Symbiosis00:58

Symbiosis

38.9K
Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
38.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct Plasmodium falciparum Erythrocyte Membrane Protein 1 Domain Cassette-Associated Antibody Gaps Specific to Cerebral Malaria and Severe Malarial Anemia.

The Journal of infectious diseases·2026
Same author

Genomic analysis of <i>Salmonella</i> Typhi from a typhoid conjugate vaccine trial.

Microbial genomics·2026
Same author

Distribution of Plasmodium falciparum apical membrane antigen-1 cluster one loop haplotypes and their association with malaria symptoms in Bandiagara, Mali.

BMC infectious diseases·2026
Same author

TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.

Vaccine·2026
Same author

Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial.

The Journal of infectious diseases·2026
Same author

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.

Vaccine·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
08:20

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes

Published on: August 17, 2022

2.8K

Vaccines against malaria.

Amed Ouattara1, Matthew B Laurens2

  • 1Department of Medicine, Center for Vaccine Development.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Developing an effective malaria vaccine is crucial for global health. Challenges include understanding immunity, parasite diversity, and finding correlates of protection for better vaccine design.

Keywords:
P. falciparumP. vivaxmalariavaccine

More Related Videos

Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
09:57

Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay

Published on: August 6, 2020

6.9K
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

640

Related Experiment Videos

Last Updated: Apr 20, 2026

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
08:20

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes

Published on: August 17, 2022

2.8K
Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
09:57

Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay

Published on: August 6, 2020

6.9K
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

640

Area of Science:

  • Malariology
  • Vaccinology
  • Immunology

Background:

  • Malaria remains a major global health challenge, necessitating novel control strategies.
  • No licensed malaria vaccine is currently available, hindering elimination efforts.
  • Significant hurdles in vaccine development include poor understanding of antimalarial immunity, lack of immune correlates of protection, and parasite genetic diversity.

Purpose of the Study:

  • To review the current status and challenges in malaria vaccine development.
  • To highlight the importance of an efficacious malaria vaccine for disease control and elimination.
  • To outline future directions for malaria vaccine research and development.

Main Methods:

  • Review of current malaria vaccine development landscape, focusing on Plasmodium falciparum.
  • Analysis of challenges including antimalarial immunity, immune correlates, and parasite diversity.
  • Evaluation of leading vaccine candidates, such as RTS,S, and their efficacy.

Main Results:

  • Current vaccine development targets pre-erythrocytic and erythrocytic stages, with ongoing research into transmission-blocking and pregnancy-associated malaria vaccines.
  • The leading pre-erythrocytic candidate, RTS,S, shows 46% efficacy against clinical malaria in Phase 3 trials.
  • Significant challenges persist due to the genetic diversity of malaria parasites and incomplete understanding of protective immunity.

Conclusions:

  • Malaria vaccine development requires addressing parasite diversity and identifying reliable correlates of protection.
  • Future efforts must focus on designing vaccines with broad efficacy against various malaria strains.
  • An effective malaria vaccine is a critical public health tool for achieving malaria elimination goals.